REHOVOT, Israel & WILMINGTON, Del.--(BUSINESS WIRE)--Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers, today announced the appointment of Gary Gordon, M.D., Ph.D., as its Chief Medical Officer.
“We are pleased to welcome Dr. Gordon to the Ayala executive team as he brings a deep understanding of cancer clinical trial execution, coupled with strong expertise in drug development,” said Roni Mamluk, Ph.D., Chief Executive Officer of Ayala. “Dr. Gordon’s wealth of knowledge and leadership will be instrumental as we work to further advance our pipeline.”
Dr. Gordon brings over 30 years of experience in oncology, drug development, R&D and clinical and regulatory affairs for both biotechnology and larger biopharmaceutical companies. Dr. Gordon joins Ayala from AbbVie, where he served as the Vice President of Oncology Development. During his time at AbbVie, Dr. Gordon oversaw the development and advancement of nearly 200 clinical studies in approximately 50 countries. Previously, he was a Divisional Vice President of Global Oncology Development, and before that the Global Project Head for PPD R&D, both at Abbott Laboratories. Prior to that role, Dr. Gordon was the Chief Scientific Officer and Vice President of Clinical Affairs at Ovation Pharmaceuticals where he spearheaded the acquisition of five drugs from Abbott.
“With an exciting pipeline and strong scientific rationale in place, I believe that Ayala’s gamma secretase inhibitors, AL101 and AL102, have the potential to offer patients with genetically-defined cancers new treatment options that they desperately need,” said Gary Gordon, M.D., Ph.D., Chief Medical Officer of Ayala. “I look forward to working with the broader team at Ayala as we work to further advance these novel programs.”
Dr. Gordon received his M.D. and Ph.D. degrees from the Johns Hopkins University School of Medicine, where he also completed his residency and postdoctoral training as well as served as an Associate Professor of Medical Oncology.
About Ayala Pharmaceuticals
Ayala Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to developing targeted cancer therapies for people living with genetically defined cancers. Ayala is broadly developing its product candidates, AL101 and AL102, best-in-class gamma secretase inhibitors, with clinical and preclinical studies underway in both solid tumors (AL101) and hematologic malignancies (AL102). Ayala’s lead product candidate, AL101, is currently in phase 2 for adenoid cystic carcinoma patients with tumor bearing Notch activating mutations (ACCURACY). For more information, visit www.ayalapharma.com